Gallery
Photos from events, contest for the best costume, videos from master classes.
 |  |
 |  |
 |  |
 |  |
 |  |
 |  |
pentin or NovoGabapentin or PMS-Gabapentin or Apo-Gabapentin or Apo Gabapentin or ApoGabapentin or Gabapentin Stada, cough or coughs, chronic cough and chronic refractory cough in English platform, and 加巴喷丁, 1-（氨甲基）环己基乙酸, 咳嗽, 慢性咳嗽, 慢 性难治性咳嗽 in Chinese platform. This systematic review showed superior efficacy and a good safety compared with placebo or standard medications in the use of gabapentin for patients with chronic cough, and further more RCTs are needed. The neuromodulator gabapentin is effective for neuropathic pain with central sensitisation, and findings from two case series have shown success with gabapentin in chronic cough. 9,10 We aimed to test whether gabapentin, given to patients with refractory chronic cough, improves cough-specific quality of life and decreases cough severity and Each study used a different intervention (gabapentin or morphine). The largest study (by Ryan et al 34) also assessed cough frequency and found that gabapentin reduced cough frequency in UCC. The consistency of these positive results indicates that centrally acting mechanisms are important in UCC and should be studied further. Gabapentin resulted in a significant improvement in cough-specific quality of life, cough severity, and cough frequency and was well tolerated; therefore, it could be considered a viable alternative to current chronic cough treatment, especially for refractory chronic cough. Gabapentin has an average rating of 6.8 out of 10 from a total of 6 reviews for the off-label treatment of Cough. 67% of reviewers reported a positive experience, while 17% reported a negative experience. Gabapentin is effective in the treatment of chronic refractory cough in both subjective and objective evaluations, and its safety is better than other neuromodulators. Keywords: Chronic refractory cough, Gabapentin, Meta-analysis, Efficacy, Safety. 1. Introduction. The trial will investigate the effect of a 10-week course of oral gabapentin 900 mg/day on refractory cough associated with interstitial lung disease (ILD) and explore the possible mechanisms involved in improving cough symptoms. In The Lancet, Nicole Ryan and colleagues 1 report on a placebo-controlled, double-blind trial of the effects of gabapentin—a drug used for epilepsy and neuropathic pain—on quality of life, cough frequency, and cough severity in people with chronic cough. Results: The effectiveness of neuromodulating medications such as gabapentin and pregabalin in the treatment of cough has been supported primarily through case series, case reports, prospective reviews and a double blind randomised controlled trial. Gabapentin results in a reduction in cough frequency and cough severity. Meta-analysis showed that gabapentin was better than placebo in cough-specific quality of life (LCQ score, MD = 4.02, 95%CI [3.26,4,78], Z = 10.34, P < 0.00001), cough severity (VAS score, MD = −29.36, 95% CI (-39.46, -19.26), Z = 5.7, P < 0.00001), cough frequency (MD = -29.87, 95% CI [- 43.84, -15.91], Z = 4.19, P < 0.0001) and therapeutic Background: Refractory chronic cough causes substantial symptoms and quality-of-life impairment. Similarities between central reflex sensitisation in refractory chronic cough and neuropathic pain suggest that neuromodulators such as gabapentin might be effective for refractory chronic cough. Despite recent clinical guidelines, the optimal therapeutic strategy for the management of refractory chronic cough is still a challenge. The present systematic review was designed to assess the evidence for efficacy and safety of gabapentin in the treatment of chronic cough. A systematic search of Amitryptiline and gabapentin for example have been shown to have some effect in reducing idiopathic cough [33,52]. The use of gabapentin in chronic cough is reviewed in this series [53]. The mechanisms of action of amitriptyline and gabapentin as treatment for neuropathic pain are likely related to their central anti-nociceptive actions. review was conducted to examine the articles concerning the use of gabapentin in the management of chronic cough. We performed the present systematic review to objectively assess the safety and efficacy of gabapentin in chronic cough so as to provide valuable references for clinical medication. Materials and Methods 1. Despite recent clinical guidelines, the optimal therapeutic strategy for the management of refractory chronic cough is still a challenge. The present systematic review was designed to assess the evidence for efficacy and safety of gabapentin in the treatment of chronic cough. Introduction Gabapentin, a neurotransmitter modulator, is thought to treat refractory cough associated with interstitial lung disease by improving cough hypersensitivity. Methods/design This is a single-center, prospective, randomized, double-blind, placebo-controlled trial. The trial will investigate the effect of a 10-week course of oral gabapentin 900 mg/day on refractory cough associated Gabapentin is effective in the treatment of chronic refractory cough in both subjective and objective evaluations, and its safety is better than other neuromodulators. If chronic cough persists even after treatment of the underlying disease, or if the chronic cough is not attributable to any cause, then a symptomatic approach with neuromodulators may be considered, with gabapentin as the first choice, and opioids or macrolides as alternatives. 1.1. The management of CC. The classification of cough is given in Table 1.. ‘Chronic cough’ is defined as a cough of more than 8 weeks’ duration. [Citation 4] CC that persists despite assessment and treatment according to an accepted guideline is termed refractory chronic cough, idiopathic chronic cough, or unexplained cough [Citation 2, Citation 3, Citation 5].
Articles and news, personal stories, interviews with experts.
Photos from events, contest for the best costume, videos from master classes.
| |
| |
| |
| |
| |
| |